JP2008535790A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008535790A5 JP2008535790A5 JP2007558290A JP2007558290A JP2008535790A5 JP 2008535790 A5 JP2008535790 A5 JP 2008535790A5 JP 2007558290 A JP2007558290 A JP 2007558290A JP 2007558290 A JP2007558290 A JP 2007558290A JP 2008535790 A5 JP2008535790 A5 JP 2008535790A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- compound
- disease
- subject
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 60
- 150000001875 compounds Chemical class 0.000 claims 39
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 23
- 150000003839 salts Chemical class 0.000 claims 23
- 229940002612 prodrug Drugs 0.000 claims 20
- 239000000651 prodrug Substances 0.000 claims 20
- -1 oxazolopyridyl Chemical group 0.000 claims 18
- 201000010099 disease Diseases 0.000 claims 13
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 208000035475 disorder Diseases 0.000 claims 10
- 210000003205 muscle Anatomy 0.000 claims 9
- 125000001424 substituent group Chemical group 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 206010022489 Insulin Resistance Diseases 0.000 claims 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 230000004584 weight gain Effects 0.000 claims 4
- 235000019786 weight gain Nutrition 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 208000006011 Stroke Diseases 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 230000002708 enhancing effect Effects 0.000 claims 3
- 210000003527 eukaryotic cell Anatomy 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 230000001965 increasing effect Effects 0.000 claims 3
- 230000000302 ischemic effect Effects 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 230000035945 sensitivity Effects 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 206010021143 Hypoxia Diseases 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 230000032683 aging Effects 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 208000015294 blood coagulation disease Diseases 0.000 claims 2
- 230000030833 cell death Effects 0.000 claims 2
- 229940044683 chemotherapy drug Drugs 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 230000004069 differentiation Effects 0.000 claims 2
- 208000030533 eye disease Diseases 0.000 claims 2
- 230000007954 hypoxia Effects 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 230000002438 mitochondrial effect Effects 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 125000002560 nitrile group Chemical group 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 125000003367 polycyclic group Chemical group 0.000 claims 2
- 108010040003 polyglutamine Proteins 0.000 claims 2
- 229920000155 polyglutamine Polymers 0.000 claims 2
- 210000000229 preadipocyte Anatomy 0.000 claims 2
- 238000011084 recovery Methods 0.000 claims 2
- 230000035882 stress Effects 0.000 claims 2
- 230000004083 survival effect Effects 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 206010000234 Abortion spontaneous Diseases 0.000 claims 1
- 206010056867 Activated protein C resistance Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 201000005657 Antithrombin III deficiency Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010008748 Chorea Diseases 0.000 claims 1
- 206010053567 Coagulopathies Diseases 0.000 claims 1
- 230000005778 DNA damage Effects 0.000 claims 1
- 231100000277 DNA damage Toxicity 0.000 claims 1
- 206010051055 Deep vein thrombosis Diseases 0.000 claims 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 1
- 208000005189 Embolism Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 208000024412 Friedreich ataxia Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 claims 1
- 206010020365 Homocystinuria Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 1
- 201000009623 Myopathy Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 208000003435 Optic Neuritis Diseases 0.000 claims 1
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- 208000032319 Primary lateral sclerosis Diseases 0.000 claims 1
- 201000005660 Protein C Deficiency Diseases 0.000 claims 1
- 206010051292 Protein S Deficiency Diseases 0.000 claims 1
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 1
- 206010038563 Reocclusion Diseases 0.000 claims 1
- 206010049771 Shock haemorrhagic Diseases 0.000 claims 1
- 208000001435 Thromboembolism Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 claims 1
- 206010046298 Upper motor neurone lesion Diseases 0.000 claims 1
- 206010047249 Venous thrombosis Diseases 0.000 claims 1
- 206010047571 Visual impairment Diseases 0.000 claims 1
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 238000002399 angioplasty Methods 0.000 claims 1
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 125000005100 aryl amino carbonyl group Chemical group 0.000 claims 1
- 230000037147 athletic performance Effects 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000023555 blood coagulation Effects 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims 1
- 230000032677 cell aging Effects 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 239000012829 chemotherapy agent Substances 0.000 claims 1
- 208000012601 choreatic disease Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 230000009089 cytolysis Effects 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- 230000020764 fibrinolysis Effects 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 208000033666 hereditary antithrombin deficiency Diseases 0.000 claims 1
- 208000013746 hereditary thrombophilia due to congenital protein C deficiency Diseases 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 208000015994 miscarriage Diseases 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 208000018360 neuromuscular disease Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 235000021049 nutrient content Nutrition 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 claims 1
- 230000008723 osmotic stress Effects 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 230000035935 pregnancy Effects 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 239000002510 pyrogen Substances 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 230000009758 senescence Effects 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 208000000995 spontaneous abortion Diseases 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
- 230000000451 tissue damage Effects 0.000 claims 1
- 231100000827 tissue damage Toxicity 0.000 claims 1
- 208000029257 vision disease Diseases 0.000 claims 1
- 230000004393 visual impairment Effects 0.000 claims 1
- CTXHOLCMGDAANM-UHFFFAOYSA-N Cc1nc2ncccc2[o]1 Chemical compound Cc1nc2ncccc2[o]1 CTXHOLCMGDAANM-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65851605P | 2005-03-03 | 2005-03-03 | |
| US70561205P | 2005-08-04 | 2005-08-04 | |
| US74178305P | 2005-12-02 | 2005-12-02 | |
| PCT/US2006/007745 WO2006094236A1 (en) | 2005-03-03 | 2006-03-03 | N-phenyl benzamide derivatives as sirtuin modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008535790A JP2008535790A (ja) | 2008-09-04 |
| JP2008535790A5 true JP2008535790A5 (enExample) | 2009-04-16 |
Family
ID=36499236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007558290A Pending JP2008535790A (ja) | 2005-03-03 | 2006-03-03 | サーチュインモジュレーターであるｎ−フェニルベンズアミド誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20090163476A1 (enExample) |
| EP (1) | EP1853610A1 (enExample) |
| JP (1) | JP2008535790A (enExample) |
| AU (1) | AU2006218404A1 (enExample) |
| CA (1) | CA2599989A1 (enExample) |
| WO (1) | WO2006094236A1 (enExample) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7504401B2 (en) | 2003-08-29 | 2009-03-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
| JP2007527418A (ja) | 2003-12-29 | 2007-09-27 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 肥満及びインシュリン耐性障害を治療又は防止するための組成物 |
| US8017634B2 (en) * | 2003-12-29 | 2011-09-13 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
| US20090142335A1 (en) * | 2005-02-15 | 2009-06-04 | Joslin Diabetes Center | Methods of diagnosis and treatment of metabolic disorders |
| US20090215681A1 (en) * | 2005-02-15 | 2009-08-27 | Joslin Diabetes Center | Methods of Diagnosis and Treatment of Metabolic Disorders |
| CA2600154A1 (en) * | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | Fluorescence polarization assays for acetyltransferase/deacetylase activity |
| US8093401B2 (en) * | 2005-08-04 | 2012-01-10 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| US8088928B2 (en) * | 2005-08-04 | 2012-01-03 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| US7855289B2 (en) * | 2005-08-04 | 2010-12-21 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| CA2618370A1 (en) * | 2005-08-04 | 2007-02-15 | Sirtris Pharmaceuticals, Inc. | Oxazolopyridine derivatives as sirtuin modulators |
| WO2007041643A1 (en) * | 2005-10-03 | 2007-04-12 | University Of Tennessee Research Foundation | Dietary calcium for reducing the production of reactive oxygen species |
| ES2389111T3 (es) * | 2005-12-02 | 2012-10-23 | Sirtris Pharmaceuticals, Inc. | Ensayos de espectrometría de masas para la actividad acetiltransferasa/desacetilasa |
| KR101472248B1 (ko) | 2006-02-10 | 2014-12-16 | 서미트 코포레이션 피엘씨 | 뒤시엔느 근이영양증의 치료 |
| WO2008024435A2 (en) * | 2006-08-23 | 2008-02-28 | Vanderbilt University | Dendritic molecular intracellular transporters and methods of making and using same |
| WO2008029152A2 (en) * | 2006-09-08 | 2008-03-13 | Summit Corporation Plc | Treatment of duchenne muscular dystrophy |
| WO2008057775A2 (en) | 2006-10-27 | 2008-05-15 | Bristol-Myers Squibb Company | Heterocyclic amide compounds useful as kinase inhibitors |
| CL2008001822A1 (es) * | 2007-06-20 | 2009-03-13 | Sirtris Pharmaceuticals Inc | Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras. |
| CL2008001821A1 (es) * | 2007-06-20 | 2009-03-13 | Sirtris Pharmaceuticals Inc | Compuestos derivados de imidazo[2,1-b]-tiazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes, sindrome metabolico, resistencia a la insulina, entre otras. |
| PE20090510A1 (es) | 2007-08-03 | 2009-05-22 | Summit Corp Plc | Combinaciones de drogas para el tratamiento de la distrofia muscular de duchenne |
| US20090239868A1 (en) * | 2007-10-23 | 2009-09-24 | Institute Of Medical Molecular Design, Inc. | Inhibitor of pai-1 production |
| WO2009054994A2 (en) * | 2007-10-23 | 2009-04-30 | President And Fellows Of Harvard College | Sirt-3 related methods and compositions for mimicking exercise |
| WO2009058348A1 (en) * | 2007-11-01 | 2009-05-07 | Sirtris Pharmaceuticals, Inc. | Amide derivatives as sirtuin modulators |
| US7868001B2 (en) * | 2007-11-02 | 2011-01-11 | Hutchison Medipharma Enterprises Limited | Cytokine inhibitors |
| EP2209496B1 (en) | 2007-11-05 | 2019-05-08 | Vanderbilt University | Multifunctional degradable nanoparticles with control over size and functionalities |
| US20130142733A1 (en) | 2007-11-05 | 2013-06-06 | Vanderbilt University | Multifunctional degradable nanoparticles with control over size and functionalities |
| US20110274620A1 (en) * | 2007-11-05 | 2011-11-10 | Harth Eva M | Multifunctional degradable nanoparticles with control over size and functionalities |
| US11254786B2 (en) | 2007-11-05 | 2022-02-22 | Vanderbilt University | Multifunctional degradable nanoparticles with control over size and functionalities |
| CN101910184A (zh) * | 2007-11-08 | 2010-12-08 | 西特里斯药业公司 | 可溶性噻唑并吡啶 |
| US8067409B2 (en) | 2007-11-27 | 2011-11-29 | Abbott Laboratories | Protein kinase inhibitors |
| RU2364597C1 (ru) * | 2007-12-14 | 2009-08-20 | Андрей Александрович Иващенко | ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ Hh-СИГНАЛЬНОГО КАСКАДА, ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АББЕРАНТНОЙ АКТИВНОСТЬЮ Hh СИГНАЛЬНОЙ СИСТЕМЫ |
| JP5425891B2 (ja) | 2008-05-01 | 2014-02-26 | サートリス ファーマシューティカルズ， インコーポレイテッド | サーチュイン調節薬としてのキノリンおよび関連する類似体 |
| AU2009266889B2 (en) | 2008-07-03 | 2013-05-02 | Glaxosmithkline Llc | Benzimidazoles and related analogs as sirtuin modulators |
| CN102227420B (zh) | 2008-09-29 | 2015-06-24 | 西特里斯药业公司 | 作为沉默调节蛋白调节剂的喹唑啉酮、喹诺酮和相关的类似物 |
| EP2179984A1 (en) * | 2008-10-27 | 2010-04-28 | Congenia S.r.l. | Acrylamido derivatives useful as inhibitors of the mitochondrial permeability transition |
| WO2010077642A1 (en) | 2008-12-08 | 2010-07-08 | Northwestern University | Method of modulating hsf-1 |
| JP5628828B2 (ja) * | 2008-12-19 | 2014-11-19 | サートリス ファーマシューティカルズ， インコーポレイテッド | チアゾロピリジンサーチュイン調節化合物 |
| KR101457027B1 (ko) | 2009-06-09 | 2014-10-31 | 캘리포니아 캐피탈 에쿼티, 엘엘씨 | 트리아진 유도체와 이들의 치료적 용도 |
| CN102573473B (zh) | 2009-06-09 | 2015-05-27 | 加利福尼亚资本权益有限责任公司 | 用作hedgehog 信号转导抑制剂的异喹啉、喹啉和喹唑啉衍生物 |
| JP2012529517A (ja) | 2009-06-09 | 2012-11-22 | アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー | ベンジル置換トリアジン誘導体類及びそれらの治療応用 |
| EP2445868B1 (en) * | 2009-06-22 | 2013-12-18 | F.Hoffmann-La Roche Ag | Biphenyl amides useful as p2x3 and/or p2x2/3 receptors modulators |
| US9556201B2 (en) | 2009-10-29 | 2017-01-31 | Glaxosmithkline Llc | Bicyclic pyridines and analogs as sirtuin modulators |
| WO2011081942A1 (en) * | 2009-12-14 | 2011-07-07 | Cornell University | Activation and activators of sirt5 |
| EP2332528A1 (de) * | 2009-12-14 | 2011-06-15 | Grünenthal GmbH | Substituierte aromatische Dicarbonsäureamide als Arzneimittel |
| WO2011111070A2 (en) * | 2010-03-09 | 2011-09-15 | Bdr Pharmaceuticals International Pvt. Ltd. | Novel injectable combination |
| EP2554163A4 (en) * | 2010-03-26 | 2013-07-17 | Univ Hokkaido Nat Univ Corp | THERAPEUTIC ACTIVE FOR NEURODEGENERATIVE DISEASES |
| WO2011130595A2 (en) * | 2010-04-15 | 2011-10-20 | Sirtris Pharmaceuticals, Inc. | Sirtuin activators and activation assays |
| RU2693462C2 (ru) | 2010-05-03 | 2019-07-03 | Курна, Инк. | Лечение заболеваний, связанных с сиртуином (sirt), путем ингибирования природного антисмыслового транскрипта к сиртуину (sirt) |
| EP2388255A1 (en) * | 2010-05-11 | 2011-11-23 | Ikerchem, S.L. | Polysubstituted benzofurans and medicinal applications thereof |
| RU2013114352A (ru) | 2010-09-15 | 2014-10-20 | Ф. Хоффманн-Ля Рош Аг | Азабензотиазолы, композиции и способы применения |
| WO2012059443A2 (en) * | 2010-11-01 | 2012-05-10 | Neurotune Ag | Novel neurotrypsin inhibitors |
| US20130261130A1 (en) * | 2010-11-01 | 2013-10-03 | Shaheen Ahmed | Neurotrypsin inhibitors |
| PH12014500198A1 (en) | 2011-07-15 | 2017-02-10 | Nusirt Sciences Inc | Compositions and methods for modulating metabolic pathways |
| US9790218B2 (en) | 2011-08-05 | 2017-10-17 | The Regents Of The University Of California | Small molecule activators of calcium-activated chloride channels and methods of use |
| WO2013074948A1 (en) | 2011-11-16 | 2013-05-23 | Resveratrol Partners, Llc | Compositions containing resveratrol and nucleotides |
| EP2793871A4 (en) * | 2011-12-23 | 2015-07-22 | Auckland Uniservices Ltd | COMPOUNDS AND METHODS FOR SELECTIVE IMAGING AND / OR ABLATION |
| CN102633668B (zh) * | 2012-01-20 | 2015-05-06 | 天舒生物技术有限公司 | 化合物在转录因子失调相关疾病的治疗药物中的应用 |
| US9198454B2 (en) | 2012-03-08 | 2015-12-01 | Nusirt Sciences, Inc. | Compositions, methods, and kits for regulating energy metabolism |
| US20150133527A1 (en) * | 2012-05-04 | 2015-05-14 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Regulation of cardiac sodium channels by sirt1 and sirt1 activators |
| JP6469015B2 (ja) | 2012-11-13 | 2019-02-13 | ニューサート サイエンシーズ， インコーポレイテッド | エネルギー代謝を増大させるための組成物および方法 |
| US9585876B2 (en) | 2013-03-15 | 2017-03-07 | Nusirt Sciences, Inc. | Leucine and nicotinic acid reduces lipid levels |
| JP2017506651A (ja) | 2014-02-27 | 2017-03-09 | ニューサート サイエンシーズ， インコーポレイテッド | 脂肪肝の低減または予防のための組成物および方法 |
| WO2015143654A1 (en) * | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
| TW201643143A (zh) * | 2015-03-13 | 2016-12-16 | 國立大學法人北海道大學 | 抑制氧化壓迫引發的神經細胞死亡之化合物 |
| CN106191215B (zh) * | 2015-04-29 | 2020-03-24 | 中国科学院上海生命科学研究院 | 肌肉萎缩相关的蛋白质分子标记Dkk-3的筛选及其应用 |
| JP6827048B2 (ja) * | 2015-12-08 | 2021-02-10 | バイオマトリカ，インク． | 赤血球沈降速度の低下 |
| US20220168337A1 (en) * | 2016-03-30 | 2022-06-02 | Hemotek, Llc | Producing atp and improving mitochondrial function in a mammal using a poly-oxygenated metal hydroxide |
| CN106117078A (zh) * | 2016-06-28 | 2016-11-16 | 东南大学 | 5‑硝基‑4‑羟基间苯二酰胺类化合物在制备抗肿瘤药物中的应用 |
| CA3038824A1 (en) * | 2016-09-28 | 2018-04-05 | Abraxis Bioscience, Llc | Methods of treating mitochondrial and metabolic disorders |
| WO2019099426A1 (en) * | 2017-11-17 | 2019-05-23 | Icahn School Of Medicine At Mount Sinai | Influenza virus inhibitor targeting nucleoprotein |
| CN108864038A (zh) * | 2018-06-12 | 2018-11-23 | 浙江大学 | 3-酰胺基-n-芳基苯甲酰胺类化合物及制备和应用 |
| EP3870292A4 (en) | 2018-10-26 | 2022-11-09 | The Research Foundation for The State University of New York | COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA |
| WO2021067393A1 (en) * | 2019-10-01 | 2021-04-08 | Memorial Sloan Kettering Cancer Center | SMALL MOLECULE INHIBITORS OF Id PROTEINS |
| IL292837B2 (en) * | 2019-12-02 | 2025-12-01 | Academia Sinica | Pdia4 inhibitors and use thereof for inhibiting ?-cell pathogenesis and treating diabetes |
| US20230086683A1 (en) * | 2020-01-15 | 2023-03-23 | Platefuse, Inc. | Platelet storage methods and compositions |
| WO2021240187A1 (en) | 2020-05-29 | 2021-12-02 | Semmelweis Egyetem | Benzamide derivatives as anti-inflammatory compounds and uses thereof |
| CN119744838B (zh) * | 2024-12-05 | 2025-12-26 | 中国农业科学院北京畜牧兽医研究所 | 蛋白质去乙酰化酶抑制剂nrd167在家禽精液超低温冷冻保存中的应用 |
| CN119867055B (zh) * | 2024-12-16 | 2025-12-26 | 中国农业科学院北京畜牧兽医研究所 | 蛋白质去乙酰化酶抑制剂3-typ在家禽精液超低温冷冻保存中的应用 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3164603A (en) * | 1965-01-05 | xnhcox | ||
| US3503929A (en) * | 1965-10-21 | 1970-03-31 | Minnesota Mining & Mfg | Polyimidazoquinazolines and polyamidobenzimidazoles |
| US3517007A (en) * | 1968-04-05 | 1970-06-23 | American Home Prod | 5 - acetamido - 4 - pyrimidinecarboxamides,5 - acetamido - 4 - pyrimidinecarboxylic acid hydrazides and related compounds |
| US3712888A (en) * | 1970-12-14 | 1973-01-23 | American Cyanamid Co | Bis-pyridoxazole-stilbene derivatives for optical brightening |
| US3828228A (en) * | 1973-03-05 | 1974-08-06 | Hewlett Packard Co | Microwave transistor package |
| US4038396A (en) * | 1975-02-24 | 1977-07-26 | Merck & Co., Inc. | Anti-inflammatory oxazole[4,5-b]pyridines |
| US4018932A (en) * | 1975-11-03 | 1977-04-19 | American Cyanamid Company | Anthelmintic pour-on formulations for topical use on domestic and farm animals |
| JPS6040016B2 (ja) * | 1977-08-31 | 1985-09-09 | コニカ株式会社 | マゼンタ色素画像の形成方法 |
| US4471040A (en) * | 1980-09-10 | 1984-09-11 | Canon Kabushiki Kaisha | Electrophotographic disazo photosensitive member |
| US4939133A (en) * | 1985-10-01 | 1990-07-03 | Warner-Lambert Company | N-substituted-2-hydroxy-α-oxo-benzeneacetamides and pharmaceutical compositions having activity as modulators of the arachidonic acid cascade |
| US5814651A (en) * | 1992-12-02 | 1998-09-29 | Pfizer Inc. | Catechol diethers as selective PDEIV inhibitors |
| ES2172585T3 (es) * | 1994-05-31 | 2002-10-01 | Mitsui Chemicals Inc | Derivado de benzoimidazol. |
| AU6966696A (en) * | 1995-10-05 | 1997-04-28 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
| US5808087A (en) * | 1995-11-29 | 1998-09-15 | Mitsui Chemicals, Inc. | Sulfonium salts of pyrrolylbenzimidazoles |
| US6653309B1 (en) * | 1999-04-26 | 2003-11-25 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme technical field of the invention |
| AU778393B2 (en) * | 1999-05-12 | 2004-12-02 | Ortho-Mcneil Pharmaceutical, Inc. | Pyrazole carboxamides useful for the treatment of obesity and other disorders |
| US6448281B1 (en) * | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| US20040010033A1 (en) * | 2001-02-20 | 2004-01-15 | Pfizer Inc. | Non-peptide GnRH agents, methods and intermediates for their preparation |
| US7081454B2 (en) * | 2001-03-28 | 2006-07-25 | Bristol-Myers Squibb Co. | Tyrosine kinase inhibitors |
| US7196095B2 (en) * | 2001-06-25 | 2007-03-27 | Merck & Co., Inc. | (Pyrimidinyl) (phenyl) substituted fused heteroaryl p38 inhibiting and PKG kinase inhibiting compounds |
| WO2003007959A1 (en) * | 2001-07-16 | 2003-01-30 | Fujisawa Pharmaceutical Co., Ltd. | Quinoxaline derivatives which have parp inhibitory action |
| WO2003011219A2 (en) * | 2001-07-27 | 2003-02-13 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| WO2004043335A2 (en) * | 2001-09-13 | 2004-05-27 | Genesoft, Inc. | Methods of treating infection by drug resistant bacteria |
| AU2002349705A1 (en) * | 2001-12-03 | 2003-06-17 | Japan Tobacco Inc. | Azole compound and medicinal use thereof |
| KR20040084896A (ko) * | 2002-02-06 | 2004-10-06 | 버텍스 파마슈티칼스 인코포레이티드 | Ｇｓｋ-3의 억제제로서 유용한 헤테로아릴 화합물 |
| ATE432261T1 (de) * | 2002-03-18 | 2009-06-15 | Merck Frosst Canada Ltd | Pde4-inhibitoren mit heterobrückensubstituiertem 8-arylchinolin |
| TW200304820A (en) * | 2002-03-25 | 2003-10-16 | Avanir Pharmaceuticals | Use of benzimidazole analogs in the treatment of cell proliferation |
| KR20040099449A (ko) * | 2002-04-18 | 2004-11-26 | 쉐링 코포레이션 | 히스타민 ｈ3 길항제로서의1-(4-피페리디닐)벤즈이미다졸론 |
| DE50312261D1 (de) * | 2002-07-12 | 2010-02-04 | Sanofi Aventis Deutschland | Heterozyklisch substituierte benzoylharnstoffe, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| TW200501960A (en) * | 2002-10-02 | 2005-01-16 | Bristol Myers Squibb Co | Synergistic kits and compositions for treating cancer |
| US20040171073A1 (en) * | 2002-10-08 | 2004-09-02 | Massachusetts Institute Of Technology | Compounds for modulation of cholesterol transport |
| EP1551809A1 (en) * | 2002-10-09 | 2005-07-13 | Pfizer Products Inc. | Pyrazole compounds for treatment of neurodegenerative disorders |
| AU2003286757B2 (en) * | 2002-11-01 | 2009-06-04 | Merck Sharp & Dohme Corp. | Carbonylamino-benzimidazole derivatives as androgen receptor modulators |
| WO2004046122A2 (en) * | 2002-11-16 | 2004-06-03 | Oxford Glycosciences (Uk) Ltd | Benzoxazole, benzthiazole and benzimidazole acid derivatives and their use as heparanase inhibitors |
| AU2003302497A1 (en) * | 2002-11-27 | 2004-06-23 | Ph. D. Edward M. Eddy | Glyceraldehyde 3-phosphate dehydrogenase-s(gapds), a glycolytic enzyme expressed only in male germ cells,is a target for male contraception |
| CA2515215A1 (en) * | 2003-02-10 | 2004-08-26 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| US7157460B2 (en) * | 2003-02-20 | 2007-01-02 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
| GEP20084341B (en) * | 2003-02-26 | 2008-03-25 | Sugen Inc | Aminoheteroaryl compounds as protein kinase inhibitors |
| JP2006519833A (ja) * | 2003-03-11 | 2006-08-31 | ファイザー・プロダクツ・インク | トランスフォーミング成長因子（ｔｇｆ）阻害剤としてのピラジン化合物 |
| US20040245539A1 (en) * | 2003-06-06 | 2004-12-09 | Tien-Yu Chen | Light-emitting diode light string |
| MXPA06002943A (es) * | 2003-09-19 | 2006-05-31 | Hoffmann La Roche | Derivados de tiazolopiridina como ligandos del receptor de adenosina. |
| US8088928B2 (en) * | 2005-08-04 | 2012-01-03 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| CA2618370A1 (en) * | 2005-08-04 | 2007-02-15 | Sirtris Pharmaceuticals, Inc. | Oxazolopyridine derivatives as sirtuin modulators |
| US8093401B2 (en) * | 2005-08-04 | 2012-01-10 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| KR20070035266A (ko) * | 2005-09-27 | 2007-03-30 | 삼성전자주식회사 | 소프트웨어 검사방법 |
| CL2008001821A1 (es) * | 2007-06-20 | 2009-03-13 | Sirtris Pharmaceuticals Inc | Compuestos derivados de imidazo[2,1-b]-tiazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes, sindrome metabolico, resistencia a la insulina, entre otras. |
| US20100168084A1 (en) * | 2008-05-08 | 2010-07-01 | Huber L Julie | Therapeutic compounds and related methods of use |
-
2006
- 2006-03-03 EP EP06736981A patent/EP1853610A1/en not_active Withdrawn
- 2006-03-03 CA CA002599989A patent/CA2599989A1/en not_active Abandoned
- 2006-03-03 WO PCT/US2006/007745 patent/WO2006094236A1/en not_active Ceased
- 2006-03-03 AU AU2006218404A patent/AU2006218404A1/en not_active Abandoned
- 2006-03-03 JP JP2007558290A patent/JP2008535790A/ja active Pending
- 2006-03-03 US US11/885,577 patent/US20090163476A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008535790A5 (enExample) | ||
| RU2315757C9 (ru) | Замещенные 2-тио-3,5-дициано-4-фенил-6-аминопиридины и лекарственное средство на их основе | |
| US20240208967A1 (en) | Pyrimidine or Pyridine Compounds, Preparation Method Therefor and Pharmaceutical Uses Thereof | |
| AU2015226855B2 (en) | Human plasma kallikrein inhibitors | |
| US9695160B2 (en) | Piperazine derivatives for treating disorders | |
| RU2594282C2 (ru) | Средства, вызывающие апоптоз, для лечения злокачественных новообразований и иммунных и аутоиммунных заболеваний | |
| JP6713928B2 (ja) | Ｕｒａｔ１阻害剤 | |
| KR20180134908A (ko) | 항-세포자멸적 bcl-2 계열 단백질의 열화를 유도하는 화합물 및 이의 용도 | |
| US20110178087A1 (en) | Compositions and Their Use as Anti-Tumor Agents | |
| JP2016505063A (ja) | ソルチリン阻害剤としてのｎ置換された５置換フタルアミド酸 | |
| KR101866706B1 (ko) | 1-알킬-6-옥소-1,6-디하이드로피리딘-3-일 화합물과 sgrm 조절인자로서의 용도 | |
| MX2012006349A (es) | Derivados de n-aciloxisulfonamida y n-hidroxi-n-acilsulfonamida. | |
| US10696661B2 (en) | Compounds | |
| KR102738491B1 (ko) | 오렉신 수용체 조정제로서의 할로-치환된 피페리딘 | |
| RU2007116850A (ru) | Антагонисты рецептора тромбина | |
| US20240398776A1 (en) | Inhibitors of tgf-beta r1 (alk5) useful to treat cell proliferation disorders | |
| CN119604488A (zh) | 一种蛋白酪氨酸激酶抑制剂及其医疗用途 | |
| KR20250004773A (ko) | Rho 관련 단백질 키나아제 억제제 및 이의 제조와 응용 | |
| KR20230157943A (ko) | Fpr1의 조절제 및 이를 사용하는 방법 | |
| JP2008519815A5 (enExample) | ||
| TW201522288A (zh) | α－取代甘胺醯胺衍生物 | |
| KR20160006717A (ko) | S100-저해제로서 유용한 n-(헤테로아릴)-설폰아미드 유도체 | |
| AU2019256672B2 (en) | Substituted propanamides as inhibitors of nucleases | |
| CN110078735B (zh) | 具有抗肿瘤活性的吡咯并嘧啶化合物及其用途 | |
| CN102603553B (zh) | 具有协同抗真菌作用的化合物及其在药学中的用途 |